Allogene's BCMA-Targeted Therapy Gets US Orphan Drug Tag For Multiple Myeloma

by Vandana Singh, Benzinga Editor

August 12, 2021 11:06 AM | 28 seconds read |

The FDA has granted Orphan Drug Designation to Allogene Therapeutics Inc's ALLO ALLO-715 to treat multiple myeloma.
In April 2021, ALLO-715 received Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA.
ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), is a potential novel treatment for multiple myeloma and other BCMA-positive malignancies.
Price Action: ALLO shares are down 2.35% at $20.75 during the market session on the last check Thursday.
Related content: Benzinga's Full FDA Calendar.